Vertex Pharmaceuticals | VRTX - Vertriebs- Und Verwaltungskosten

Aktienkurs
469.34
Täglich Wechseln
-8.79 -1.84%
Monatlich
-1.67%
Jährlich
-7.02%
Q1 Prognose
455.17




Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.89B 325M 2025-12
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.75B 831M 2025-12
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.31B 134M 2025-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12